The pathogenesis, diagnosis and treatment of lupus nephritis

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: Renal involvement is a major cause of morbidity and mortality in systemic lupus erythematosus. In this review, we provide an update on recent discoveries in the pathogenesis, diagnosis, and treatment of lupus nephritis. RECENT FINDINGS: Localized long-lived plasma cells have been identified as playing an important role in lupus nephritis. In addition, the roles of aberrant expression of microRNAs and proinflammatory cytokines have been explored. Early diagnosis is important for effective treatment and multiple biomarkers have been identified; however, none has been yet validated for clinical use. Biomarker panels may turn out to be more accurate than each individual component. Biologic agents for the treatment of lupus nephritis are being studied, including belimumab which was recently approved for nonrenal systemic lupus erythematosus. Rituximab has not proven itself in large, placebo-controlled trials, although it is still being used in refractory cases of lupus nephritis. SUMMARY: Lupus nephritis is a potentially devastating complication of systemic lupus erythematosus. Immune cells, cytokines, and epigenetic factors have all been recently implicated in lupus nephritis pathogenesis. These recent discoveries may enable a paradigm shift in the treatment of this complex disease, allowing the tailoring of treatment to target specific pathogenic mediators at specific points in time in the progression of disease. VIDEO ABSTRACT:

Original languageEnglish (US)
Pages (from-to)502-509
Number of pages8
JournalCurrent Opinion in Rheumatology
Volume26
Issue number5
DOIs
StatePublished - 2014

Fingerprint

Lupus Nephritis
Systemic Lupus Erythematosus
Therapeutics
Biomarkers
Cytokines
Biological Factors
Plasma Cells
MicroRNAs
Epigenomics
Disease Progression
Early Diagnosis
Placebos
Morbidity
Kidney
Mortality

Keywords

  • biomarkers
  • long-lived plasma cells
  • lupus nephritis
  • microRNA

ASJC Scopus subject areas

  • Rheumatology

Cite this

The pathogenesis, diagnosis and treatment of lupus nephritis. / Schwartz, Noa; Goilav, Beatrice; Putterman, Chaim.

In: Current Opinion in Rheumatology, Vol. 26, No. 5, 2014, p. 502-509.

Research output: Contribution to journalArticle

@article{1e074e396ee546ab999668334439a20a,
title = "The pathogenesis, diagnosis and treatment of lupus nephritis",
abstract = "PURPOSE OF REVIEW: Renal involvement is a major cause of morbidity and mortality in systemic lupus erythematosus. In this review, we provide an update on recent discoveries in the pathogenesis, diagnosis, and treatment of lupus nephritis. RECENT FINDINGS: Localized long-lived plasma cells have been identified as playing an important role in lupus nephritis. In addition, the roles of aberrant expression of microRNAs and proinflammatory cytokines have been explored. Early diagnosis is important for effective treatment and multiple biomarkers have been identified; however, none has been yet validated for clinical use. Biomarker panels may turn out to be more accurate than each individual component. Biologic agents for the treatment of lupus nephritis are being studied, including belimumab which was recently approved for nonrenal systemic lupus erythematosus. Rituximab has not proven itself in large, placebo-controlled trials, although it is still being used in refractory cases of lupus nephritis. SUMMARY: Lupus nephritis is a potentially devastating complication of systemic lupus erythematosus. Immune cells, cytokines, and epigenetic factors have all been recently implicated in lupus nephritis pathogenesis. These recent discoveries may enable a paradigm shift in the treatment of this complex disease, allowing the tailoring of treatment to target specific pathogenic mediators at specific points in time in the progression of disease. VIDEO ABSTRACT:",
keywords = "biomarkers, long-lived plasma cells, lupus nephritis, microRNA",
author = "Noa Schwartz and Beatrice Goilav and Chaim Putterman",
year = "2014",
doi = "10.1097/BOR.0000000000000089",
language = "English (US)",
volume = "26",
pages = "502--509",
journal = "Current Opinion in Rheumatology",
issn = "1040-8711",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - The pathogenesis, diagnosis and treatment of lupus nephritis

AU - Schwartz, Noa

AU - Goilav, Beatrice

AU - Putterman, Chaim

PY - 2014

Y1 - 2014

N2 - PURPOSE OF REVIEW: Renal involvement is a major cause of morbidity and mortality in systemic lupus erythematosus. In this review, we provide an update on recent discoveries in the pathogenesis, diagnosis, and treatment of lupus nephritis. RECENT FINDINGS: Localized long-lived plasma cells have been identified as playing an important role in lupus nephritis. In addition, the roles of aberrant expression of microRNAs and proinflammatory cytokines have been explored. Early diagnosis is important for effective treatment and multiple biomarkers have been identified; however, none has been yet validated for clinical use. Biomarker panels may turn out to be more accurate than each individual component. Biologic agents for the treatment of lupus nephritis are being studied, including belimumab which was recently approved for nonrenal systemic lupus erythematosus. Rituximab has not proven itself in large, placebo-controlled trials, although it is still being used in refractory cases of lupus nephritis. SUMMARY: Lupus nephritis is a potentially devastating complication of systemic lupus erythematosus. Immune cells, cytokines, and epigenetic factors have all been recently implicated in lupus nephritis pathogenesis. These recent discoveries may enable a paradigm shift in the treatment of this complex disease, allowing the tailoring of treatment to target specific pathogenic mediators at specific points in time in the progression of disease. VIDEO ABSTRACT:

AB - PURPOSE OF REVIEW: Renal involvement is a major cause of morbidity and mortality in systemic lupus erythematosus. In this review, we provide an update on recent discoveries in the pathogenesis, diagnosis, and treatment of lupus nephritis. RECENT FINDINGS: Localized long-lived plasma cells have been identified as playing an important role in lupus nephritis. In addition, the roles of aberrant expression of microRNAs and proinflammatory cytokines have been explored. Early diagnosis is important for effective treatment and multiple biomarkers have been identified; however, none has been yet validated for clinical use. Biomarker panels may turn out to be more accurate than each individual component. Biologic agents for the treatment of lupus nephritis are being studied, including belimumab which was recently approved for nonrenal systemic lupus erythematosus. Rituximab has not proven itself in large, placebo-controlled trials, although it is still being used in refractory cases of lupus nephritis. SUMMARY: Lupus nephritis is a potentially devastating complication of systemic lupus erythematosus. Immune cells, cytokines, and epigenetic factors have all been recently implicated in lupus nephritis pathogenesis. These recent discoveries may enable a paradigm shift in the treatment of this complex disease, allowing the tailoring of treatment to target specific pathogenic mediators at specific points in time in the progression of disease. VIDEO ABSTRACT:

KW - biomarkers

KW - long-lived plasma cells

KW - lupus nephritis

KW - microRNA

UR - http://www.scopus.com/inward/record.url?scp=84905459899&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905459899&partnerID=8YFLogxK

U2 - 10.1097/BOR.0000000000000089

DO - 10.1097/BOR.0000000000000089

M3 - Article

C2 - 25014039

AN - SCOPUS:84905459899

VL - 26

SP - 502

EP - 509

JO - Current Opinion in Rheumatology

JF - Current Opinion in Rheumatology

SN - 1040-8711

IS - 5

ER -